Jay M. Short
Net Worth

Last updated:

What is Jay M. Short net worth?

The estimated net worth of Dr. Jay M. Short is at least $20,218,985 as of 20 Dec 2023. He owns shares worth $546,928 as insider, has earned $15,432,057 from insider trading and has received compensation worth at least $4,240,000 in BioAtla, Inc..

What is the salary of Jay M. Short?

Dr. Jay M. Short salary is $1,060,000 per year as Co-Founder, Chief Executive Officer & Chairman in BioAtla, Inc..

How old is Jay M. Short?

Dr. Jay M. Short is 67 years old, born in 1958.

What stocks does Jay M. Short currently own?

As insider, Dr. Jay M. Short owns shares in one company:

Company Title Shares Price per share Total value
BioAtla, Inc. (BCAB) Co-Founder, Chief Executive Officer & Chairman 1,439,283 $0.38 $546,928

What does BioAtla, Inc. do?

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB logo
BCAB
BioAtla, Inc.
$0.38

Jay M. Short insider trading

BioAtla, Inc.

Dr. Jay M. Short has made 15 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he purchased 50,000 units of BCAB stock worth $106,900 on 20 Dec 2023.

The largest trade he's ever made was exercising 78,697 units of BCAB stock on 14 Jun 2021. As of 20 Dec 2023 he still owns at least 1,439,283 units of BCAB stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 50,000 $2.14 $106,900
Purchase
Common Stock 40,800 $2.47 $100,858
Purchase
Common Stock 26,350 $7.84 $206,610
Purchase
Common Stock 40,308 $2.91 $117,296
Purchase
Common Stock 29,082 $2.79 $81,052
Sale
Common Stock 4,811 $22.11 $106,352
Sale
Common Stock 24,321 $23.23 $564,855
Sale
Common Stock 18,490 $24.68 $456,407
Sale
Common Stock 15,435 $23.89 $368,742
Sale
Common Stock 17,022 $24.94 $424,546
Sale
Common Stock 24,943 $25.16 $627,566
Sale
Common Stock 15,675 $26.24 $411,234
Option
Employee Stock Option (right to buy) 7,747 $18 $139,446
Option
Common Stock 7,747 $18 $139,446
Sale
Common Stock 4,533 $41.6 $188,573
Sale
Common Stock 55,000 $39.23 $2,157,375
Sale
Common Stock 19,269 $39.22 $755,749
Sale
Common Stock 35,417 $39.71 $1,406,232
Sale
Common Stock 32,023 $40.21 $1,287,773
Sale
Common Stock 78,697 N/A N/A
Sale
Common Stock 78,697 $42.42 $3,338,327
Sale
Common Stock 78,697 $42.42 $3,338,327

BioAtla key executives

BioAtla, Inc. executives and other stock owners filed with the SEC: